Effects of Hormone Replacement Therapy on Left Ventricular Hypertrophy and Growth-Promoting Factors in Hypertensive Postmenopausal Women

Miya, Yoshinori; Sumino, Hiroyuki; Ichikawa, Shûichi; Nakamura, Toshio; Kanda, Tsugiyasu; Kumakura, Hisao; Takayama, Yoshiaki; Mizunuma, Hideki; Sakamaki, Tatsuya; Kurabayashi, Masahiko

doi:10.1291/hypres.25.153

Cited by 34 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to oral HRT, a few studies have shown that oral HRT decreases office BP (11,16) and ABP (11,12). But most studies demonstrate that oral HRT does not reduce office BP (17)(18)(19)(20)(21)(22)(23)(24)(25) or ABP (16,18), which is in keeping with the results of the present study. In two studies (10,15), a differential BP response to oral and transdermal estrogen has been described, demonstrating that transdermal HRT reduces ABP, but oral HRT does not affect office BP.…”

Section: Discussionsupporting

confidence: 91%

“…Echocardiographic left ventricular mass is greater in patients who have high nighttime ABP (33). Many studies (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) have investigated the effects of oral or transdermal HRT on BP in normotensive or hypertensive postmenopausal women. In these studies, transdermal HRT reduced 24-h ambulatory (9,15), daytime (8,10,13,14), or nighttime BP (6,7,9,10,14) without reducing office BP.…”

Section: Discussionmentioning

confidence: 99%

“…Assessment of 24-h ambulatory blood pressure monitoring (ABPM) provides more information concerning an individual's prevailing BP than conventional "office" BP measurements. In studies assessing the association between HRT and BP (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25), the majority of subjects were Caucasian or African while a small number of individuals were Asian, especially Japanese. These studies have investigated the effect of HRT on BP based only on the use of office BP measurements in hypertensive or normotensive Japanese postmenopausal women (20)(21)(22)(23)(24)(25).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Hormone Replacement Therapy on Office and Ambulatory Blood Pressure in Japanese Hypertensive Postmenopausal Women

Sumino

Ichikawa²,

Kumakura³

et al. 2003

Hypertens Res

Self Cite

View full text Add to dashboard Cite

in postmenopausal women are poorly understood. HRT has been reported to decrease (6-16) or not to change (17-25) BP in normotensive and hypertensive postmenopausal women. The lack of an effect might be dependent on the type, dose, and route of estrogen and progesterone used as well as the methods used for the measurement of BP.HRT has been considered relatively contraindicated for patients with hypertension. This stems from the observed hypertensive effects of oral contraceptives, documented in the 1970s (26,27). Because hypertension is considered a major risk factor for the development of cardiovascular disease

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Hormone Replacement Therapy on Office and Ambulatory Blood Pressure in Japanese Hypertensive Postmenopausal Women

Sumino

Ichikawa²,

Kumakura³

et al. 2003

Hypertens Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…10 In humans, pregnancy-related rises in oestrogen are associated with rises in ACE activity [11][12] whilst exogenous oestrogen administration to postmenopausal women (PMW) is consistently and durably associated with reduced serum ACE activity [13][14][15][16][17][18][19][20][21] with the greatest reductions amongst those with the highest initial ACE levels.…”

Section: Introductionmentioning

confidence: 99%

“…14 Such effects may be mediated through inhibition of ACE messenger ribonucleic synthesis 18 or alterations in the cleavage of membrane-bound ACE. Meanwhile, the presence (Insertion, I) rather than absence (Deletion, D) of a 287 bp fragment in the ACE gene is associated with lower serum 22 and tissue 23 ACE activity, and (although this is debated 24,25 ) with reduced cardiovascular risk.…”

Section: Introductionmentioning

confidence: 99%

Lack of change in serum angiotensin-converting enzyme activity during the menstrual cycle

Sanders¹,

Harris²,

Gohlke

et al. 2006

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

PaperAbstract I In nt tr ro od du uc ct ti io on n. . The Deletion (D) rather than Insertion (I) variant of the angiotensin-converting enzyme (ACE) gene is associated with higher circulating ACE activity. Meanwhile, coronary risk rises with the menstrual nadir in oestrogen levels, exogenous oestrogen reduces serum ACE activity (with a greater reduction the higher the baseline ACE activity), and pharmacological reduction in ACE activity is cardioprotective. Alterations in coronary risk associated with the menstrual cycle may thus be mediated through (genotype-dependent) changes in ACE activity.We have examined this hypothesis. M Ma at te er ri ia al ls s a an nd d m me et th ho od ds s. . Twenty-three healthy female subjects (12 II, 11 DD genotype) were studied. None were taking oral contraceptive agents. Blood was assayed for oestrogen, follicle stimulating hormone (FSH), luteinising hormone (LH), progesterone and ACE activity every three days throughout their menstrual cycle. Results ACE activity was unrelated to oestrogen, FSH or LH during the menstrual cycle, irrespective of ACE genotype. C Co on nc cl lu us si io on ns s. . The increase in myocardial ischaemia during low oestrogen phases of the menstrual cycle does not appear mediated through a fall in serum ACE activity. IntroductionCoronary atherosclerosis is less prevalent in premenopausal women than in men, 1-2 and acute coronary events are more frequent during the oestrogen nadir coinciding with the menses.

show abstract

ERβ targets ZAK and attenuates cellular hypertrophy via SUMO‐1 modification in H9c2 cells

Pai

Shibu

Chang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Aberrant expression of leucine zipper- and sterile ɑ motif-containing kinase (ZAK) observed in pathological human myocardial tissue is associated with the progression and elevation of hypertrophy. Our previous reports have correlated high levels of estrogen (E2) and abundant estrogen receptor (ER) α with a low incidence of pathological cardiac-hypertrophy and heart failure in the premenopause female population. However, the effect of elevated ERβ expression is not well known yet. Therefore, in this study, we have analyzed the cardioprotective effects and mechanisms of E2 and/or ERβ against ZAK overexpression-induced cellular hypertrophy. We have used transient transfection to overexpress ERβ into the ZAK tet-on H9c2 cells that harbor the doxycycline-inducible ZAK plasmid. The results show that ZAK overexpression in H9c2 cells resulted in hypertrophic effects, which was correlated with the upregulation of p-JNK and p-p38 MAPKs and their downstream transcription factors c-Jun and GATA-4. However, ERβ and E2 with ERβ overexpressions totally suppressed the effects of ZAK overexpression and inhibited the levels of p-JNK, p-p38, c-Jun, and GATA-4 effectively. Our results further reveal that ERβ directly binds with ZAK under normal conditions; however, ZAK overexpression reduced the association of ZAK-ERβ. Interestingly, increase in ERβ and E2 along with ERβ overexpression both enhanced the binding strengths of ERβ and ZAK and reduced the ZAK protein level. ERβ overexpression also suppressed the E3 ligase-casitas B-lineage lymphoma (CBL) and attenuated CBL-phosphoinositide 3-kinase (PI3K) protein association to prevent PI3K protein degradation. Moreover, ERβ and/or E2 blocked ZAK nuclear translocation via the inhibition of small ubiquitin-like modiﬁer (SUMO)-1 modification. Taken together, our results further suggest that ERβ overexpression strongly suppresses ZAK-induced cellular hypertrophy and myocardial damage.

show abstract

Effects of Hormone Replacement Therapy on Left Ventricular Hypertrophy and Growth-Promoting Factors in Hypertensive Postmenopausal Women

Cited by 34 publications

References 37 publications

Effects of Hormone Replacement Therapy on Office and Ambulatory Blood Pressure in Japanese Hypertensive Postmenopausal Women

Effects of Hormone Replacement Therapy on Office and Ambulatory Blood Pressure in Japanese Hypertensive Postmenopausal Women

Lack of change in serum angiotensin-converting enzyme activity during the menstrual cycle

ERβ targets ZAK and attenuates cellular hypertrophy via SUMO‐1 modification in H9c2 cells

Contact Info

Product

Resources

About